Aspiriant LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Aspiriant LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 26.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,213 shares of the company’s stock after acquiring an additional 456 shares during the quarter. Aspiriant LLC’s holdings in Zoetis were worth $374,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Zoetis by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company’s stock worth $7,960,912,000 after purchasing an additional 536,477 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Wellington Management Group LLP raised its holdings in Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after purchasing an additional 297,044 shares in the last quarter. Capital World Investors raised its holdings in Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after purchasing an additional 57,798 shares in the last quarter. Finally, Norges Bank bought a new position in Zoetis in the fourth quarter worth $980,646,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Trading Up 3.3 %

Zoetis stock opened at $176.51 on Friday. The business has a 50-day simple moving average of $167.68 and a two-hundred day simple moving average of $178.94. The company has a market cap of $80.54 billion, a P/E ratio of 34.01, a P/E/G ratio of 2.65 and a beta of 0.88. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 EPS. Analysts predict that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus lowered their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. The Goldman Sachs Group lowered their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Barclays lowered their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. Finally, HSBC lowered their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.